Glucophage (Metformin)

Medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist — Updated April 2026

What Is Glucophage (Metformin)? — Primary Indication and Canadian Context

Glucophage is the brand name of Merck's metformin hydrochloride formulation. Generic metformin is available under multiple names at Canadian pharmacies. Metformin is a biguanide — a class of antidiabetic agents with a distinct mechanism of action from all other diabetes medications. It is Health Canada-approved for treatment of type 2 diabetes mellitus in adults, and is widely used off-label for polycystic ovary syndrome (PCOS) and prediabetes prevention.

Type 2 diabetes affects approximately 3.7 million Canadians — roughly 10% of the population — with an additional 7–8 million Canadians estimated to have prediabetes. The Canadian health system spends approximately $30 billion annually on diabetes and its complications. Early, effective glucose control with metformin has been shown to significantly reduce the risk of microvascular complications (retinopathy, nephropathy, neuropathy) and — uniquely among antidiabetic agents — macrovascular complications including heart attack and stroke.

How Metformin Works — The AMPK Mechanism

Metformin's primary mechanism of action is inhibition of mitochondrial complex I (NADH dehydrogenase) in hepatocytes, which reduces hepatic ATP production and increases the AMP:ATP ratio. This activates AMPK (AMP-activated protein kinase) — an enzyme sometimes called the cellular energy sensor or the body's metabolic master switch.

Three primary glucose-lowering mechanisms result from AMPK activation:

• Suppression of hepatic gluconeogenesis (primary mechanism): The liver is the dominant source of fasting blood glucose through gluconeogenesis — the production of new glucose from non-carbohydrate substrates (amino acids, lactate, glycerol). In type 2 diabetes, hepatic gluconeogenesis is markedly elevated due to insulin resistance and relative glucagon excess. Metformin reduces hepatic glucose output by 25–30% — directly reducing fasting plasma glucose, which is the primary driver of elevated HbA1c in most Canadian type 2 diabetics
• Improved peripheral insulin sensitivity: Metformin increases glucose uptake in skeletal muscle and adipose tissue by improving GLUT4 transporter translocation to the cell surface — reducing postprandial glucose spikes and improving insulin sensitivity without stimulating additional insulin secretion from the pancreas
• Reduced intestinal glucose absorption: Metformin modestly reduces glucose absorption from the gastrointestinal tract, contributing to its postprandial glucose-lowering effect

Why metformin does not cause hypoglycemia: Unlike insulin or sulfonylureas (glyburide, glipizide), metformin does not stimulate insulin secretion from the pancreas. It works only on insulin-dependent pathways that are already activated by endogenous insulin. This means metformin cannot push blood glucose below normal levels — making hypoglycemia essentially impossible with metformin monotherapy. This is one of its most clinically important safety advantages.

Clinical Evidence — What the Studies Show

UKPDS (UK Prospective Diabetes Study) — the landmark trial: The most important clinical evidence base for metformin. In overweight newly diagnosed type 2 diabetics, metformin reduced myocardial infarction risk by 39%, diabetes-related death by 42%, and all-cause mortality by 36% compared to diet alone — effects not seen with sulfonylureas or insulin at equivalent glucose control. These macrovascular benefits appear to be partially independent of glucose lowering, suggesting metformin has direct cardioprotective mechanisms beyond HbA1c reduction.

HbA1c reduction: Metformin typically reduces HbA1c by 1.0 to 2.0 percentage points from baseline — sufficient to bring many Canadian patients from diagnosed diabetes (HbA1c ≥6.5%) to target range (HbA1c <7.0% per Diabetes Canada guidelines) as monotherapy.

Weight neutrality to modest weight loss: Unlike insulin and most sulfonylureas, metformin is weight-neutral or produces modest weight loss (typically 1–3 kg). Some studies suggest metformin reduces appetite and food intake independently of its glucose-lowering effects. For the majority of Canadian type 2 diabetics who are overweight or obese, this is a significant practical advantage.

TAME trial (Targeting Aging with Metformin) — ongoing: A landmark US clinical trial testing whether metformin can delay the onset of age-related chronic diseases (cardiovascular disease, cancer, dementia, physical disability) in non-diabetic older adults. This trial reflects growing scientific interest in metformin's potential longevity effects through AMPK activation, autophagy enhancement, and anti-inflammatory mechanisms. Results are anticipated within the next several years.

Metformin vs Other Diabetes Medications Available in Canada

Dosage Schedule — How to Take Metformin Correctly

Starting dose and titration — the key to tolerability: The most common reason Canadian patients stop metformin early is gastrointestinal side effects (nausea, diarrhoea) — which are largely preventable with proper low-and-slow titration. Starting at a full dose immediately dramatically increases GI side effects and early discontinuation.

Standard titration protocol:

• Week 1–2: 500mg once daily with the evening meal
• Week 3–4: 500mg twice daily (morning and evening meals)
• Week 5–6: 850mg twice daily or 500mg three times daily — if glucose targets not met
• Maximum dose: 2,550mg per day in divided doses. Most Canadian patients achieve adequate glucose control at 1,500–2,000mg daily

Always take metformin with food: Taking metformin with or immediately after a meal substantially reduces GI side effects by slowing gastric absorption. Never take metformin on an empty stomach.

Metformin IR vs Metformin XR (Extended Release/Glucophage XR): Metformin XR is the same active ingredient in a slow-release formulation that releases metformin over 8–10 hours rather than 2–4 hours for immediate-release. XR produces significantly fewer GI side effects (nausea, diarrhoea) at the cost of slightly less HbA1c reduction per mg. Many Canadian patients who cannot tolerate IR metformin can tolerate XR at the same dose. XR is taken once daily with the evening meal. Note: do not crush or chew XR tablets — they must be swallowed whole to maintain the extended-release mechanism.

Missed dose: Take as soon as remembered with food. If it is almost time for the next dose, skip the missed dose. Never double up. For XR taken once daily — if missed entirely, skip and resume next day.

Off-Label Uses of Metformin in Canada

Polycystic Ovary Syndrome (PCOS): Metformin is one of the most widely used off-label treatments for PCOS — a hormonal disorder affecting 8–13% of Canadian women of reproductive age. In PCOS, insulin resistance drives excess androgen production from the ovaries. Metformin reduces insulin levels, which in turn reduces androgen production, improving menstrual regularity, reducing hirsutism, and improving fertility outcomes. Typical metformin doses for PCOS: 500mg to 2,000mg daily. Evidence supports metformin's use for PCOS in combination with lifestyle modification, and it is endorsed in Canadian PCOS management guidelines.

Prediabetes / Diabetes Prevention: The Diabetes Prevention Program (DPP) trial demonstrated that metformin reduced progression from prediabetes to type 2 diabetes by 31% over 3 years (compared to 58% for lifestyle intervention). Canadian Diabetes guidelines recommend considering metformin for high-risk prediabetic individuals — particularly those who are unable to achieve sufficient weight loss through lifestyle alone, are under 60, have a BMI over 35, or have gestational diabetes history.

Gestational Diabetes: Metformin is increasingly used in gestational diabetes in Canada as an alternative to insulin — it crosses the placenta, which raises theoretical concerns, but clinical data show it is safe and effective for both mother and baby in well-selected patients. Always managed by an obstetrician.

Antipsychotic-induced weight gain: Metformin is used off-label in Canadian psychiatric practice to mitigate weight gain and metabolic syndrome caused by second-generation antipsychotics (olanzapine, clozapine, quetiapine).

Critical Safety Information — Lactic Acidosis and Renal Function

Lactic acidosis — the most serious but rare risk: Lactic acidosis is a buildup of lactic acid in the bloodstream caused by impaired metformin clearance. Metformin is excreted unchanged by the kidneys — if kidney function is significantly impaired, metformin accumulates and impairs mitochondrial function in other tissues, leading to lactic acid buildup. Lactic acidosis is rare (approximately 3–10 cases per 100,000 patient-years) but serious, with a mortality rate of approximately 50% if untreated. The vast majority of cases occur in patients who should not have been prescribed metformin — those with severely impaired renal function, liver disease, or heart failure.

Renal function (eGFR) thresholds — critical for all Canadian metformin users:

• eGFR ≥60 mL/min/1.73m²: Metformin can be used at full doses — no restriction
• eGFR 45–59 mL/min/1.73m²: Metformin can be continued at current dose — monitor renal function every 3–6 months
• eGFR 30–44 mL/min/1.73m²: Reduce metformin dose by 50% — monitor renal function every 3 months. Consider switching to Metformin XR which may have marginally better tolerability
• eGFR <30 mL/min/1.73m²: Metformin is contraindicated — stop immediately

Hold metformin before contrast dye procedures: Iodinated contrast media used in CT scans, cardiac catheterizations, and angiograms can temporarily impair renal function. Canadian radiological guidelines recommend holding metformin for 48 hours before contrast procedures in patients with eGFR 30–60, and resuming only after confirming renal function is stable.

Hold metformin during major illness: Any condition causing dehydration, hypoperfusion, or acute renal impairment (severe vomiting/diarrhea, major surgery, serious infection, heart failure exacerbation) reduces metformin clearance. Metformin should be held during such illnesses — the "sick day rule" endorsed by Diabetes Canada.

Side Effects — What Canadian Patients Commonly Experience

Very common — affect up to 30% of patients starting metformin:

• Nausea — most common, especially in the first 2–4 weeks. Dramatically reduced by taking with food and using low-and-slow dose titration. Usually resolves with continued use
• Diarrhoea and loose stools — related to metformin's effects on gut transit and the intestinal microbiome. Taking with food and slow titration minimise this
• Abdominal discomfort / bloating
• Metallic taste in the mouth — a distinctive and commonly reported side effect, usually mild and transient

Important — Vitamin B12 deficiency (long-term users): Metformin reduces vitamin B12 absorption from the gut by interfering with calcium-dependent ileal membrane transport. Clinically significant B12 deficiency develops in approximately 5–10% of long-term metformin users (after 5+ years). B12 deficiency can cause peripheral neuropathy, fatigue, cognitive impairment, and macrocytic anaemia — symptoms that can be mistakenly attributed to diabetic neuropathy. Diabetes Canada recommends periodic B12 level monitoring (every 2–3 years) in patients on long-term metformin. If B12 is low or borderline — supplement with oral cyanocobalamin 500–1000mcg daily or consider IM B12 injections.

Uncommon — affect less than 1 in 100 patients:

• Decreased appetite and modest weight loss (often welcomed by Canadian patients)
• Elevated liver transaminases (rare, usually transient)

Rare but serious:

• Lactic acidosis — see critical safety section above. Symptoms: unusual muscle pain, difficulty breathing, stomach discomfort, feeling cold, dizziness, or feeling very weak. Stop metformin and call 911 or go to nearest ER immediately if these symptoms develop
• Severe hypoglycemia — not caused by metformin monotherapy. Risk only when combined with insulin or sulfonylureas

Drug Interactions — Important for Canadian Patients

Interactions increasing lactic acidosis risk:

• Iodinated contrast media — hold metformin before and 48 hours after contrast procedures (see above)
• Diuretics (furosemide, hydrochlorothiazide) — can cause dehydration and reduce renal perfusion, impairing metformin clearance. Monitor renal function and hydration
• NSAIDs (ibuprofen, naproxen) — reduce renal blood flow, impair metformin clearance. Use with caution, especially in elderly Canadian patients
• ACE inhibitors/ARBs — commonly prescribed for blood pressure and kidney protection in Canadian diabetics. Can reduce GFR — monitor renal function when initiating

Interactions increasing hypoglycemia risk (when combined with metformin):

• Insulin — the combination of metformin + insulin is extremely common in Canadian clinical practice. Insulin doses often need reduction when metformin is added, as metformin reduces hepatic glucose production
• Sulfonylureas (glyburide, gliclazide) — commonly combined with metformin in Canadian practice. The combination works well for glucose control but carries hypoglycemia risk from the sulfonylurea component
• Alcohol (heavy use) — alcohol inhibits gluconeogenesis, potentiating metformin's hepatic glucose-lowering effect and increasing lactic acidosis risk. Moderate alcohol (1–2 drinks) is generally acceptable; heavy alcohol use is contraindicated

Interactions affecting metformin blood levels:

• Cimetidine (Tagamet) — inhibits renal tubular secretion of metformin, increasing metformin exposure by approximately 50%. Clinical significance is modest in patients with normal renal function but relevant in those with borderline renal function
• Topiramate, verapamil, ranolazine — also inhibit OCT2/MATE transporters involved in metformin renal excretion. Monitor for increased metformin effects

Who Should Not Take Metformin

Metformin is contraindicated in:

• Patients with eGFR <30 mL/min/1.73m² (severe renal impairment)
• Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis
• Patients with severe hepatic impairment — metformin relies on normal hepatic lactate metabolism
• Patients with known lactic acidosis or history of lactic acidosis on metformin
• Patients with acute decompensated heart failure requiring hospitalisation — haemodynamic instability impairs renal perfusion and metformin clearance
• Patients undergoing iodinated contrast procedures — hold metformin before and 48 hours after (as above)
• Patients with severe acute illness causing dehydration or haemodynamic instability — sick day rule applies

Use with caution in: Elderly Canadians (reduced renal reserve — check eGFR before prescribing and every 6–12 months), patients on nephrotoxic medications, patients with alcohol use disorder, patients with history of heart failure (stable heart failure is not a contraindication; only acute decompensated HF).

Vitamin B12 Monitoring — Practical Guide for Long-Term Canadian Users

Any Canadian who has taken metformin for more than 2–3 years should discuss B12 monitoring with their physician or pharmacist. The test is simple — a serum B12 level on a routine blood draw. Normal B12 levels are generally above 200 pmol/L (Canadian lab reference ranges vary slightly). Levels below 150 pmol/L indicate deficiency requiring supplementation. Levels between 150–200 pmol/L are borderline — supplementation is prudent.

Supplementation options: Oral cyanocobalamin 500–1000mcg daily is effective for most patients (absorption is via passive diffusion at these doses, bypassing the metformin-impaired ileal transport mechanism). Intramuscular B12 injections every 3 months provide reliable repletion for patients with more severe deficiency or poor oral absorption. B12 supplementation does not require stopping metformin.

Health Canada Status and Provincial Drug Coverage

Health Canada status: Metformin hydrochloride is a Schedule F prescription drug in Canada, approved for treatment of type 2 diabetes mellitus in adults. A valid Canadian prescription from a physician, nurse practitioner, or pharmacist (in provinces with expanded prescribing authority) is required at regulated Canadian pharmacies.

Provincial coverage — metformin is one of the most widely covered drugs in Canada:

• Ontario (ODB): Covered for eligible recipients — seniors, Ontario Works, ODSP. Generic metformin is on the ODB formulary at the lowest available price
• British Columbia (BC PharmaCare): Covered under Fair PharmaCare for eligible patients
• Quebec (RAMQ): Covered for RAMQ cardholders
• Alberta: Covered under the Alberta Drug Benefit List for eligible patients
• Most private Canadian employer insurance plans: Generic metformin is almost universally covered — it is one of the lowest-cost medications on formulary

Our recommendation: Generic metformin at Canadian pharmacies is extremely affordable — often less than $10–20 per month with provincial coverage. Check your provincial drug plan or private insurance before purchasing online. If you do not have coverage or want to ensure supply continuity, drugs-canada.com offers competitive pricing with discreet delivery across Canada.

Delivery to All Canadian Provinces

drugs-canada.com ships discreetly to all Canadian provinces and territories. Standard delivery: 4–9 business days.

Ontario (Toronto, Ottawa, Mississauga, Hamilton, Brampton) — British Columbia (Vancouver, Victoria, Surrey, Kelowna) — Quebec (Montreal, Quebec City, Laval, Gatineau) — Alberta (Calgary, Edmonton, Red Deer) — Manitoba (Winnipeg) — Saskatchewan (Saskatoon, Regina) — Nova Scotia (Halifax) — New Brunswick (Moncton, Fredericton) — and all remaining provinces and territories.

All orders are delivered in plain, unmarked packaging with no reference to the contents or sender. A tracking number is included with every order.

Frequently Asked Questions — Metformin (Glucophage) in Canada

Is Glucophage the same as metformin? Yes — Glucophage is the brand name of Merck's metformin hydrochloride formulation. Generic metformin contains the identical active ingredient at the same dose and is bioequivalent. The vast majority of Canadian patients prescribed metformin receive the generic — which is therapeutically identical and significantly less expensive.

Does metformin cause weight loss? Metformin is weight-neutral to producing modest weight loss of approximately 1–3 kg in most patients. It does not cause the significant weight loss of GLP-1 agonists (Ozempic, Rybelsus). Unlike insulin and sulfonylureas, metformin does not cause weight gain. For the majority of Canadian type 2 diabetics who are overweight, weight neutrality is a significant advantage over other antidiabetic agents.

Can metformin cause low blood sugar (hypoglycemia)? No — metformin monotherapy does not cause hypoglycemia because it does not stimulate insulin secretion. It reduces glucose production in the liver and improves insulin sensitivity — mechanisms that cannot push blood glucose below normal levels. Hypoglycemia risk only arises when metformin is combined with insulin or sulfonylureas.

How long does it take for metformin to lower blood sugar? Fasting blood glucose begins to fall within 1–2 weeks of starting metformin at therapeutic doses. HbA1c (which reflects average glucose over 3 months) takes 3 months of consistent treatment to show full effect. Most Canadian patients see meaningful HbA1c reduction at their first follow-up lab after 3 months of treatment.

What is the difference between Glucophage and Glucophage XR? Glucophage (IR) releases metformin immediately after ingestion — producing peak blood levels in 2–4 hours. It requires multiple daily doses and produces more GI side effects. Glucophage XR releases metformin slowly over 8–10 hours, taken once daily with the evening meal. XR produces significantly fewer GI side effects at equivalent doses. XR must be swallowed whole — do not crush, chew, or split XR tablets.

Can I take metformin with alcohol? Moderate alcohol consumption (1–2 standard drinks) is generally acceptable with metformin for most Canadian patients. Heavy alcohol use is contraindicated — alcohol inhibits hepatic gluconeogenesis (the same pathway metformin targets) and can increase lactic acidosis risk. Heavy drinking while on metformin also risks significant hypoglycemia when combined with food restriction or missed meals.

Do I need to stop metformin before surgery or a CT scan? Yes — metformin should be held before surgical procedures and before CT scans using iodinated contrast dye. For elective surgery: hold metformin on the day of surgery and resume when eating normally and renal function confirmed normal post-op. For contrast procedures: hold 48 hours before (if eGFR 30–60) and do not resume until 48 hours after, with confirmed stable renal function.

Is metformin safe during pregnancy? Metformin is used in pregnancy for gestational diabetes and PCOS — it crosses the placenta but clinical data show no harmful effects on the baby in these contexts. However, any metformin use in pregnancy must be under obstetric supervision. Insulin remains the reference standard for gestational diabetes management in Canada.

How long does delivery to Canada take? Standard delivery to all Canadian provinces takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to contents or sender. Every order includes a tracking number.